Proactive Investors - Run By Investors For Investors

Renovo ends Prevascar development

Renovo ends Prevascar development

Renovo (LON:RNVO) today confirmed that it will now perform any further work on Prevascar following the completion of a clinical trial.

The company says that it will continue to focus on its merger and acquisition plans and its share buy-back programme as a way to enhance shareholder value.

The clinical trial results follow the disappointing results of the Juvista trial in February 2011. Subsequently, Renovo’s remaining trials which had already been contracted had continued.

Today, Renovo reported that 56 patients were enrolled in the trial of the Prevascar scar treatment. It said there was a ‘small but significant’ reduction in scar width compared to placebo after one month, however by month 12 there was in fact a ‘small but significant’ improvement in the placebo scar width compared to Prevascar. 

Meanwhile, most other assessments showed no difference between treatments. 

In November, Renove told investors that it was considering all options to maximise value including acquisitions and mergers of external companies.


Jamie Ashcroft
April 16 2012 Jamie Ashcroft

Register here to be notified of future RNVO Company articles


December 13 2012
December 15 2011
November 18 2011

Related Articles

October 16 2014

Nanobiotix said it has received approval from French regulators to embark on phase II/III registration of its lead product.

June 02
Redx Pharma has unveiled a potential breakthrough in the fight against antibiotic resistant infections.
June 06 2014

Sphere Medical has received the final approval that paves the way for the commercial launch of its breakthrough blood monitor later this year.

© Proactive Investors 2015